Xenleta™ (lefamulin), developed by Nabriva Therapeutics, has been approved by the US FDA for adults with community-acquired bacterial pneumonia, marking the first new antibiotic with a novel mechanism of action to be approved in nearly two decades.
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
In this infographic we give you a visual snapshot of the antibiotics introduced for gonorrhea and a timeline of when resistance was first identified, in addition to setting out some of the primary resistance mechanisms.
Could board games be used as an educational tool to help teach and raise awareness around some of the major challenges in infectious diseases? In this interview we speak to Salam Abbara about the game she has helped develop, which aims to help medical students learn and understand antibiotic prescribing.
Take a look at this month’s industry headlines including an FDA approval for Zebraxa, new…
New research, presented at ASM Microbe (20—24 June 2019, San Francisco, CA, USA), has suggested that public campaigns have largely been ineffective at reducing antibiotic prescribing.
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
Take a look at our latest infographic where Annabelle Lopez explains what antibiotics are, how resistance occcurs and what the consequences might be without any action.
Giving a single dose of preventative antibiotics after assisted childbirth could prevent almost half of maternal infections and also reduce antibiotic use by infection prevention, according to a new trial.
